Integra LifeSciences and University of Pennsylvania To Present Results of LICOX Brain Tissue Oxygen Monitoring Clinical Experi

Integra LifeSciences and University of Pennsylvania To Present Results of LICOX Brain Tissue Oxygen Monitoring Clinical Experience At the 2006

Posted By Scarlett Law Group || 22-Sep-2006

American Association of Neurological Surgeons — AANS — Annual Meeting in San Francisco

PLAINSBORO, N.J., April 25, 2006 (PRIMEZONE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that the Department of Neurosurgery and Surgery, University of Pennsylvania will present the results of seven clinical studies on the application of the LICOX(R) Brain Tissue Oxygen Monitoring System to the management of brain injured patients, including those with severe traumatic brain injury or subarachnoid hemorrhage at the 2006 American Association of Neurological Surgeons (AANS) Annual Meeting in San Francisco, CA, this week.

The key findings of these studies include the following:

— Conventional strategies of ICP and CPP management may result in
significant reductions in cerebral oxygenation despite what would
otherwise be considered adequate intracranial pressure and
cerebral perfusion.

— Occult cerebral hypoxia occurs in TBI patients who receive
neurocritical care despite traditional practices to maintain CPP.
Medical interventions other than those to treat ICP and CPP can
improve BtO2. These interventions increase the number of possible
therapies for severe TBI in the intensive care unit.

— Occult cerebral hypoxia occurs in SAH patients who receive
conventional neurocritical care. Interventions to augment CPP and
FiO2 can help to maintain cerebral oxygenation in poor grade SAH
patients.

— SAH patients require a higher CPP than TBI patients to maintain
cerebral oxygenation. Guidelines developed for TBI may not be
applicable for SAH.

— CPP values do not always ensure adequate cerebral oxygenation
after SAH.

— Poor outcome in older patients after SAH may be associated with
a greater daily duration of brain hypoxia. In addition, older
patients appear to respond less to pressor treatments to augment
BtO2 than young patients.

— Fluid therapy to increase CVP does not ensure cerebral
oxygenation in all patients during the first 25 hours after SAH.
“Since we started using the LICOX(R) Brain Tissue Oxygen Monitoring System in 2002 we have found it to be a useful addition to existing neuromonitoring methods. In addition to our experience in TBI, we now have added considerable experience in SAH patients, where LICOX(R) seems to be a useful tool too,” said Peter D. LeRoux M.D., FACS, Associate Professor and Vice Chairman, Department of Neurosurgery, University of Pennsylvania.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients’ quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have research, manufacturing and distribution facilities located throughout the world. We have approximately 1,400 employees. Please visit our website at http://www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the use of the LICOX(R) Brain Tissue Oxygen Monitoring System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use the LICOX(R) Brain Tissue Oxygen Monitoring System may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading “Factors That May Affect Our Future Performance” included in the Business section of Integra’s Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President
Chief Administrative Officer
(609) 936-2481
[email protected]
Maria Platsis, Senior Director of Corporate Development
and Investor Relations
(609) 936-2333
[email protected]

Source : http://www.primezone.com/newsroom/news.html?d=97878

Blog Home
  • 2015 Litigator Awards Ranked Top 1% Lawyers